220679-09-4

Usage

Uses

Used in Pharmaceutical Industry:
4-(3-METHYL-4-NITRO-PHENYL)MORPHOLINE is used as an intermediate in the synthesis of pharmaceuticals for its ability to participate in various chemical reactions, contributing to the development of new drugs and medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(3-METHYL-4-NITRO-PHENYL)MORPHOLINE is utilized as an intermediate in the production of agrochemicals, leveraging its chemical properties to enhance the effectiveness of agricultural products.
Used in Organic Compounds Synthesis:
4-(3-METHYL-4-NITRO-PHENYL)MORPHOLINE is employed as a key intermediate in the synthesis of other organic compounds, where its structural features facilitate molecular modifications and the creation of diverse chemical entities.

Upstream product

• 110-91-8 morpholine 
• 52415-00-6 4-iodo-2-methyl-1-nitro-benzene 
• 446-33-3 5-Fluoro-2-nitrotoluene 

Downstream Products

• 581-00-0 2-Methyl-4-morpholin-4-ylphenylamine 
• 1024611-36-6 (2-methyl-4-morpholin-4-yl-phenyl)-(6-thiazol-2-yl-quinazolin-4-yl)-amine 
• 1246529-64-5 4-[(2-{[2-methyl-4-(morpholin-4-yl)phenyl]amino}-9H-purin-6-yl)amino]cyclohexanol 
• 1246529-78-1 6-(cyclohexyloxy)-N-[2-methyl-4-(morpholin-4-yl)phenyl]-9H-purin-2-amine 
• 1395172-00-5 C₂₇H₃₇N₇O₃ 
• 1395172-03-8 C₂₉H₄₀N₈O₄ 
• 1395172-07-2 C₂₅H₃₃N₇O₃ 
• 1395172-17-4 C₃₁H₄₄N₈O₃ 
• 1383810-38-5 C₂₁H₂₈N₈O 
• 1246529-35-0 ethyl 4-[(2-{[2-methyl-4-(morpholin-4-yl)phenyl]amino}-9H-purin-6-yl)amino]piperidine-1-caxboxylate 
• 1246532-46-6 N₆-cyclohexyl-N₂-(2-methyl-4-morpholin-4-yl-phenyl)-9-(tetrahydropyran-2-yl)-9H-purine-2,6-diamine 
• 1383810-36-3 C₂₀H₂₅N₇O₂ 
• 1383810-33-0 C₂₃H₃₂N₈O 
• 1383810-31-8 C₂₃H₃₀N₆O 

Relevant academic research and scientific papers

A class of FLT3 kinase inhibitors, preparation and application thereof

The invention relates to a class of FLT3 kinase inhibitors, preparation and application thereof, wherein specifically the compound has a structure represented by a formula (I), and all groups and substituents are defined in the specification. The invention also discloses a preparation method of the compound, and application of the compound in inhibition of FLT3.

Quinoline derivative, and preparation method and uses thereof

The invention relates to a quinoline derivative, and a composition including the derivative, and also relates to a preparation method of the derivative, and uses of the derivative in the prevention ortreatment of harmful fungi and the killing of pests.

Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors

Efforts to optimize biological activity, novelty, selectivity and oral bioavailability of Mps1 inhibitors, from a purine based lead MPI-0479605, are described in this Letter. Mps1 biochemical activity and cytotoxicity in HCT-116 cell line were improved. On-target activity confirmation via mechanism based G2/M escape assay was demonstrated. Physico-chemical and ADME properties were optimized to improve oral bioavailability in mouse.

QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I) are found to be active in inhibiting replication of flaviviridae viruses, R is C1-C4 alkyl or C1-C4 alkoxy.

Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complications

Recent efforts to identify treatments for chronic diabetic complications have resulted in the discovery of a novel series of highly potent and selective 3-[(benzothiazol-2-yl)methyl]indole-N-alkanoic acid aldose reductase inhibitors. The lead candidate, 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat, 9) inhibits aldose reductase with an IC50 of 5 nM, while being 5400 times less active against aldehyde reductase, a related enzyme involved in the detoxification of reactive aldehydes. It lowers nerve and lens sorbitol levels with ED50's of 1.9 and 4.5 mg/kg/d po, respectively, in the 5-day STZ-induced diabetic rat model. In a 3-month diabetic intervention model (1 month of diabetes followed by 2 months of drug treatment at 5 mg/kg/d po), it normalizes polyols and reduces the motor nerve conduction velocity deficit by 59% relative to diabetic controls. It has a favorable pharmacokinetic profile (F, 82%; t1/2, 5.6 h; Vd, 0.694 L/kg) with good drug penetration in target tissues (Cmax in sciatic nerve and eye are 2.36 and 1.45 μg equiv/g, respectively, when dosed with [14C] lidorestat at 10 mg/kg po).

MORPHOLINYLANILINOQUINAZO- LINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS

Compounds of formula (Ia) are found to be active in inhibiting replication of flaviviridae viruses, wherein R1, R2, R3 and R4 are as defined in the claims.

Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids

Disclosed are methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis, the methods comprising administration of substituted indolealkanoic acids to patients in need of such treatment. Also disclosed are such compounds use

Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor

Disclosed are methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis, the methods comprising administration of substituted indolealkanoic acids to patients in need of such treatment. Also disclosed are such compounds use

Methods for reducing uric acid levels

Disclosed are methods of reducing serum uric acid levels, the methods comprising administration of substituted indolealkanoic acids to patients in need of such treatment. Also disclosed are such compounds useful in the treatment of gout and related diseas

Substituted indolealkanoic acids

Disclosed are substituted indolealkanoic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as we